What is the recommended albumin dose and infusion duration for an adult with acute kidney injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Albumin Dosing in AKI with Hepatorenal Syndrome

For adults with AKI and cirrhosis, administer albumin 1 g/kg/day (maximum 100 g/day) for 2 consecutive days when serum creatinine doubles from baseline, followed by 20-40 g daily if hepatorenal syndrome (HRS-AKI) is diagnosed and creatinine remains elevated. 1, 2

Initial Management: Stage 1-2 AKI

When AKI is first diagnosed in a cirrhotic patient:

  • Withdraw diuretics, NSAIDs, and nephrotoxic drugs immediately
  • Administer albumin 1 g/kg/day for 2 days if serum creatinine shows doubling from baseline 1, 2
  • Maximum daily dose should not exceed 100 g 2
  • This serves both as treatment and diagnostic challenge to differentiate volume-responsive AKI from HRS-AKI

Treatment of Confirmed HRS-AKI (Stage 2-3)

If creatinine remains >2× baseline after initial 2-day albumin challenge:

Day 1:

  • Albumin 1 g/kg IV (loading dose) 1, 2

Subsequent days:

  • Albumin 20-40 g daily 1, 2
  • Continue until creatinine returns to ≤0.3 mg/dL above baseline for 2 consecutive days, or for maximum 14 days 1
  • Always combine with vasoconstrictors (terlipressin, norepinephrine, or midodrine/octreotide) 1

Infusion Duration and Monitoring

Critical safety consideration: The standard dose (1.5 g/kg day 1 g/kg day 3) infused over 6 hours is poorly tolerated in many patients, with high rates of circulatory overload 3. The most recent evidence shows:

  • Infuse albumin over prolonged periods (not specified in guidelines, but >6 hours based on safety data)
  • Monitor closely for pulmonary edema—this is the primary risk 1, 4
  • Stop infusion immediately if respiratory distress develops 3
  • Use clinical assessment of volume status (vital signs, urine output, echocardiography, or CVP if central line present) 1

Context-Specific Dosing

For spontaneous bacterial peritonitis (SBP) with AKI:

  • 1.5 g/kg within 6 hours of diagnosis
  • 1 g/kg on day 3 1, 5
  • Particularly beneficial if baseline creatinine >1.0 mg/dL or bilirubin >4 mg/dL 6, 5

For large-volume paracentesis (>5L):

  • 8 g albumin per liter of ascites removed 7, 4
  • Consider this dose even for <5L if patient has ACLF or high AKI risk 7

Important Caveats

General AKI without cirrhosis: Albumin is not recommended for routine volume expansion in AKI. The 2013 KDIGO guidelines explicitly suggest using isotonic crystalloids rather than colloids (including albumin) as initial management 8. This is a grade 2B recommendation.

Exceptions where albumin is appropriate:

  • Cirrhosis with complications (as detailed above)
  • Hepatorenal syndrome diagnostic criteria require albumin challenge 8

Avoid albumin in:

  • Traumatic brain injury (associated with harm) 8
  • General critical illness without cirrhosis 4
  • Cardiac surgery (recent 2026 meta-analysis shows increased AKI risk with 20-25% albumin) 9

Practical Algorithm

  1. Diagnose AKI stage (creatinine rise ≥0.3 mg/dL in 48h or ≥1.5× baseline)
  2. Remove precipitants (diuretics, nephrotoxins)
  3. If creatinine doubled: Give albumin 1 g/kg/day × 2 days (max 100 g/day)
  4. Reassess at 48 hours:
    • If improved: Continue monitoring
    • If creatinine remains >2× baseline: Diagnose HRS-AKI
  5. For HRS-AKI: Albumin 1 g/kg day 1, then 20-40 g daily + vasoconstrictors
  6. Continue until: Creatinine ≤0.3 mg/dL above baseline × 2 days OR 14 days maximum

The evidence strongly supports this approach specifically for cirrhotic patients, where albumin serves multiple functions beyond volume expansion, including anti-inflammatory effects and binding of vasoactive substances 1, 2. However, the general AKI population should receive crystalloids as first-line therapy 8.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.